Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, June 18, 2013 - Astellas Pharma Inc. (Tokyo: 4503; “Astellas”) and Kyoto University’s Center for iPS Cell Research and Application (Director: Dr. Shinya Yamanaka; “CiRA”), as a...
TOKYO, June 14, 2013 - Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) announced today that it has been granted approval in Japan for the additional...
TOKYO, Japan, June 11, 2013 -Astellas Pharma Inc. (TSE: 4503) today announced that AVEO has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) informing the...
Read more about Complete Response Letter for Tivozanib New Drug Application in Renal Cell Carcinoma
Tokyo, June 5, 2013 - Zeria Pharmaceutical Co., Ltd. (Tokyo: 4559; “Zeria”) and Astellas Pharma Inc. (Tokyo: 4503; “Astellas”) announced today that Acofide® Tablets 100mg (nonproprietary...
Read more about Launch of Acofide® in Japan for Treating Functional Dyspepsia
Tokyo and San Francisco, CA – June 3, 2013 – Astellas Pharma Inc. (TSE: 4503) and Medivation, Inc. (Nasdaq: MDVN) today announced that after a priority review, Health Canada has approved XTANDI®
Tokyo Japan, May 31, 2013 - Nippon Boehringer Ingelheim Co., Ltd. (headquartered in Shinagawa-ku, Tokyo; president, Yoshiaki Aono; hereinafter referred to as “Nippon Boehringer Ingelheim”) and...
THOUSAND OAKS, Calif., and TOKYO (May 29, 2013) – Amgen (NASDAQ:AMGN), the world’s largest independent biotechnology company, and Astellas Pharma Inc. (Tokyo Stock Exchange: 4503,...
Tokyo, May 28, 2012 – Astellas Pharma Inc. (Tokyo:4503) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to isavuconazole for the treatment of...
Read more about Astellas announces isavuconazole orphan drug designation by U.S. FDA
Tokyo, Japan and San Francisco, CA – May 24, 2013 – Astellas Pharma Inc. (TSE: 4503) and Medivation, Inc. (NASDAQ: MDVN) today announced that Astellas has submitted an application for...
SOUTH SAN FRANCISCO, Calif. and NORTHBROOK, Ill. – May 14, 2013 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and Astellas Pharma US, Inc. (“Astellas”), a U.S....
CAMBRIDGE, Mass. and TOKYO, Japan, May 15, 2013 - AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that additional data from the Phase 3 TIVO-1 trial (TIvozanib...
Tokyo, Japan, May 14, 2013 - Astellas Pharma Inc. (Tokyo：4503, President and CEO: Yoshihiko Hatanaka, hereinafter called “Astellas”) today announced plans to reshape its research framework...
Read more about Reshaping research framework to enhance the ability to generate innovative drugs
Tokyo, Japan, May 13, 2013 – Astellas Pharma Inc. (Tokyo: 4503; President and CEO: Yoshihiko Hatanaka, hereinafter called “the Company”) announced that at the meeting of the Board of...
Read more about Astellas Announces Cancellation of Treasury Stock
Tokyo, May 8, 2013 – Astellas Pharma Inc. (Astellas; Tokyo: 4503) today announced its selection results based on a3 (a-cube), a website (http://www.astellas.com/jp/a-cube/) launched on May 17,...
TOKYO, JAPAN and BRIDGEWATER, N.J., May 7, 2013 – Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) and Drais Pharmaceuticals, Inc. (“Drais”) today announced that they have entered into a...
Read more about Astellas and Drais Partner To Develop Third Astellas Compound through Tacurion
CAMBRIDGE, Mass. and TOKYO, Japan, May 2, 2013 - AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today reported that the U.S. Food and Drug Administration’s (FDA) Oncologic...
Chertsey, England and San Francisco, CA; 26 April, 2013: Today, Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. (Nasdaq:...
Read more about POSITIVE CHMP OPINION FOR XTANDITM (ENZALUTAMIDE) IN ADVANCED PROSTATE CANCER1
TOKYO, April 15, 2013 - Astellas Pharma Inc. (“Astellas”; Tokyo: 4503) today announced that Songlin Xue, M.D., Ph.D. has been named head of Global Pharmacovigilance (GPV). Dr. Xue will be...
Read more about New Hire Reinforces Global Compliance Structure
TOKYO, April 10, 2013 - Astellas Pharma Inc. (“Astellas”; Tokyo:4503) announced today that its collaborative research project with Johns HopkinsUniversity School of Medicine (“JHU”;...
Follow us
